tbuckley/cabot-search huggingface dataset:
Abstract 15500: Persistent Gender Bias in Use of Reperfusion Therapy in STEMI Patients: Data from the FAST-MI Program 1995-2010
Authors: Tabassome Simon, Etienne Puymirat, Marianne Zeller, Francois Schiele, Sandrine Charpentier, Florence Leclercq, Pascal Gueret, Eric Bonnefoy-Cudraz, Jean Ferrieres, Nicolas Danchin
Journal: Circulation (2014)

Introduction: Previous studies have shown that women receive less reperfusion therapy for STEMI. To determine whether this gender bias persists over time, we assessed 15-year trends in use of primary PCI and reperfusion therapy, and one-year mortality in women (W) vs men (M) presenting with STEMI.

Methods: The FAST-MI program consists of 4 one-month nationwide French surveys conducted 5 years apart from 1995 to 2010, with a similar methodology and including all AMI patients admitted to general, academic or private hospitals.

Results: Of the 6707 STEMI patients included, 1811 were W (27%). Mean age decreased in W (74±12 to 71±15 years, P=0.006) as in M (63±14 to 61±14 years, P<0.001), and % of W <55 years doubled (from 8.4% to 17.5%). Management evolved regardless of sex: primary PCI increased from 7% to 56% in W and from 14% to 62% in M, while fibrinolysis decreased from 25.5% to 12% (W) and from 42% to 14.5% (M). Early use of recommended medications significantly increased in W and M: antiplatelet (W: 88% to 96%; M: 94% to 98%), low molecular weight heparin (W: 0 to 58%; M: 0 to 64%), beta-blockers (W: 51.5% to 74.5%; M: 70.5 to 83%), ACE-I (W: 44% to 55%; M: 49% to 62%) and statins (W: 6% to 86%; M: 11% to 91%). In the overall cohort, reperfusion therapy was less used in W (adjusted OR vs M: 0.75, 0.70-0.85), and the trend did not substantially change over time (OR: 0.63, 0.47-0.83 in 1995, and 0.74, 0.55-0.99 in 2010).

One-year mortality (Fig 1) decreased from 29% to 14% in W (HR adjusted on baseline profile 2010 vs 1995: 0.52, 0.37-0.74, P<0.001), and from 14% to 6% in M (adjusted HR 0.40, 0.29-0.54, P<0.001). Use of primary PCI was associated with lower one-year mortality both in W (adjusted HR 0.63, 0.45-0.90, P=0.01) and M (adjusted HR 0.74, 0.57-0.96, P=0.02).

Conclusion: Reperfusion therapy is associated with lower one-year mortality regardless of sex, but remains underused in women. Avoiding this persistent gender bias would likely result in further improving survival in women.

   ![][1]  [1]: /embed/graphic-1.gif
Psychosomatic Medicine
Authors: R. Karstens
Journal: Psychotherapy and Psychosomatics (1973)

Basically, we meet different kinds of difficulties when trying to integrate psychosomatic medicine into the services of a traditional university hospital: first, there are a lot of real obstacles, and second, there are more or less hidden resistances in the involved persons and institutions which present themselves via rationalization disguised as real obstacles or which accentuate the obstacles of the first category. Using examples of both sorts of difficulties from our own experience, it will be discussed which fundamental problems have to be considered before the attempt to overcome the cited difficulties has a chance of being successful.
Onikomikoz tedavisinde pulse ve sürekli terbinafin karşılaştırılması: Randomize, çift-kör, plasebo kontrollü bir çalışma
Authors: Erin M. Warshaw, sup>Debra D. Fett, Hanna E. Bloomfield, sup> Joseph P. Grill, David B. Nelson, Vicente Quintero, Susan M. Carver, Gary R. Zielke, veFrank A. Lederle
Journal: Journal of the American Academy of Dermatology (2006)
Acute Hematogenous Osteomyelitis
Authors: E B SELF
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metronomic irinotecan and standard FOLFIRI regimen as first-line chemotherapy in metastatic colorectal cancer (MCRC). Final results of phase II study
Authors: M. Nardi, D. Azzarello, P. Del Medico, R. Giannicola, A. Falzea, C. Giuffrè, R. Maisano, V. Panuccio, M. Raffaele, M. Zavettieri, A. Avallone
Journal: Journal of Clinical Oncology (2007)

14520 Background: Angiogenesis is necessary to sustain the growth of both the primary tumour and the development of metastases in colorectal cancer. Before the clinical use of bevacizumab, metronomic chemotherapy was the only mean to block the growth of tumor microvessel. CPT-11 showed, in preclinical model, to have antiangiogenetic properties using low doses and weekly administration. We carried out this study in order to evaluate the activity and toxicity of mixed metronomic and standard FOLFIRI regimen in MCRC. Methods: From 10/03 to 9/05 we treated 46 pts (24M 22F), median age 66 years (range 41–79), ECOG PS 0–2 with this schedule: CPT- 11 10 mg/mq days 1, 7, 10 and CPT-11 150 mg/mq day 2, l-Folinic Acid 100 mg/mq days 2 and 3, 5-FU 400 mg/mq bolus days 2 and 3 and 5- FU 600 mg/mq 44 hours c.i. days 2 and 3 every two weeks for a maximum of 12 cycles. Results: All pts have been evaluable activity and toxicity. We obtained 9 CR (20%), 12 PR (26%) with an ORR of 46% (CI 95%: ±13%) and 17 SD. After a median follow-up of 24 months we registered a median TTP of 10 months and a median OS of 22 months. As regard toxicity, the chemotherapy has been well tolerated; no toxic deaths occurred and no therapy ended for toxicity. 6 pts had 25% dose reduction (standard schedule) for diarrhea G4 after the first cycle. The main toxicities recorded on a total of 440 cycles (cy) delivered were: diarrhea G4 1.7% and G3 2.3% of the cy. Neutropenia G3 5.8% and vomiting G3 0.5% of the cy. Anemia G2 was recorded in 14 pts. All pts suffered from partial alopecia and half of the pts from mild oral mucositis. Conclusions: This mixed schedule seems to be active and well tolerated, ORR, TTP and OS are similar to Hurwitz results (NEJM 2004; 350: 2335–42) but with less adverse events. The combination of this schedule with bevacizumab deserves further studies. No significant financial relationships to disclose.
Abstract 12206: Plasma Pentraxin 3 is Associated with Presence of Thin-cap Fibroatheroma in Coronary Culprit Lesion Determined by Optical Coherence Tomography
Authors: Seiji Koga, Satoshi Ikeda, Tomoo Nakata, Tomohiko Yasunaga, Koji Maemura
Journal: Circulation (2010)

Backgroud: Vascular inflammation and oxidative stress play key roles in vulnerability of atherosclerotic plaque. Thin-cap fibroatheroma (TCFA) is the primary type of vulnerable plaque. However, inf...
Sewage Yields Clues to SV40 Transmission
Authors: Brian Vastag
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THROMBOCYTOPENIC PURPURA ASSOCIATED WITH DISCOID LUPUS ERYTHEMATOSUS AND RENAL GLOMERULAR CHANGES
Authors: Morton H. Edelman
Journal: Annals of Internal Medicine (1941)

Case Reports1 July 1941THROMBOCYTOPENIC PURPURA ASSOCIATED WITH DISCOID LUPUS ERYTHEMATOSUS AND RENAL GLOMERULAR CHANGESMORTON H. EDELMAN, M.D.MORTON H. EDELMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-15-1-116 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe occurrence of thrombocytopenia associated with lupus erythematosus has been referred to by Templeton,1Lyon,2Baehr, Klemperer and Schifrin,3Ginzler and Fox,4Keil,5and others. However, it had been previously observed by Libman and Sachs6in the second of the four cases, which they reported in 1924 and which for want of a better name, they called atypical verrucous endocarditis. Up to the present thrombocytopenia and the accompanying thrombocytopenic purpura have been considered by many one of the visceral or systemic manifestations of the disseminated form of lupus erythematosus. Further, the chronic fixed variety of lupus erythematosus has been considered...Bibliography1. TEMPLETON HJ: Thrombopenia in acute disseminated lupus erythematosus, Arch. Dermat. and Syph., 1934, xxix, 700-702. CrossrefGoogle Scholar2. LYON JM: Acute lupus erythematosus, Am. Jr. Dis. Child., 1933, xlv, 572-583. Google Scholar3. BAEHRKLEMPERERSCHIFRIN GPA: A diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis, Trans. Assoc. Am. Phys., 1935, l, 139-155. Google Scholar4. GINZLERFOX AMII: Disseminated lupus erythematosus, cutaneous manifestation of a systemic disease (Libman-Sachs), report of a case, Arch. Int. Med., 1940, lxv, 26-50. CrossrefGoogle Scholar5. KEIL H: Relation between "systemic" lupus erythematosus and a peculiar form of thrombocytopenic purpura, Brit. Jr. Dermat., 1937, xliv, 221-237. CrossrefGoogle Scholar6. LIBMANSACHS EB: A hitherto undescribed form of valvular and mural endocarditis, Arch. Int. Med., 1924, xxxiii, 701-737. CrossrefGoogle Scholar7. STICKNEYKEITH JMNM: Renal involvement in disseminated lupus erythematosus, Arch. Int. Med., 1940, lxvi, 643-660. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication February 27, 1941.From the Department of Medicine, Jewish Hospital, Brooklyn, New York, Service of Dr. E. L. Shlevin. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe heart in systemic lupus erythematosusTHE NATURAL HISTORY OF LUPUS ERYTHEMATOSUS AND ITS MODIFICATION BY CORTISONE AND CORTICOTROPHIN (A.C.T.H.) 1 July 1941Volume 15, Issue 1Page: 116-123KeywordsEndocarditisHospital medicineLupus erythematosus ePublished: 1 December 2008 Issue Published: 1 July 1941 PDF downloadLoading ...
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy
Authors: M. Pollicita, C. Alteri, M.C. Bellocchi, D. Armenia, L. Carioti, R. Salpini, L. Colagrossi, A. Battisti, M. Aragri, L. Fabeni, R. Mariani, M. Dalessandro, A. Ranelli, M. Paoloni, G. Parruti, C.F. Perno, V. Svicher
Journal: Clinical Microbiology and Infection (2015)
Systemic Tools Can Improve Cardiac Care
Authors: Mike Mitka
Journal: JAMA (2005)

effectiveness and no safety data.” Anne Honebrink, MD, assistant professor of obstetrics and gynecology in the School of Medicine at the University of Pennsylvania Health System, Philadelphia, said her clinical experience runs contrary to the panel’s conclusion that depression, sleep problems, and cognitive complaints are not related to estrogen loss. “In some women, these symptoms are pretty clearly menopause-related, and they clearly respond to estrogen,” she said. Donna Shoupe, MD, professor of obstetrics and gynecology in the Keck School of Medicine at the University of Southern California, Los Angeles, said she disagrees with the panel’s assessment that menopause should not be considered a condition that requires routine medical care. “It should be automatic to offer estrogen as an option,” she said. “We need to educate women about what’s available and not scare them with the WHI.” The panel emphasized that until many of the information gaps are filled, women and their physicians should make treatment decisions based on individual risk factors and the best data available. The panel’s report is available online at http://consensus.nih.gov. The evidence review is available at http://www .ahrq.gov/clinic/tp/menopstp.htm.
Abstract 13740: Significance of Chronic Low-Grade Inflammation and Diabetes Mellitus (DM) for Coronary Spasm Following Drug-Eluting Stent Implantation in Patients with Coronary Heart Disease (CHD)
Authors: Seiji Hokimoto, Tomonori Akasaka, Yuichiro Arima, Koichi Kaikita, Kazuko Nakagawa, Hisao Ogawa
Journal: Circulation (2014)

Background: Coronary spasm is a manifestation of coronary endothelial dysfunction characterized by transient total or subtotal occlusion or severe diffuse vasoconstriction of an epicardial artery and contributes importantly to the pathogenesis of coronary heart disease (CHD). Coronary spasm and diabetes mellitus (DM) are reported to be associated with low-grade inflammation. However, it is unknown about the relation between chronic inflammation and DM in atherosclerotic high-risk patients following drug-eluting stent (DES) implantation. The aim was to examine the relation between coronary spasm and chronic inflammation or DM. Methods: We performed intracoronary acetylcholine test for coronary spasm provocation in 60 consecutive patients (41 male, age 69.1±9.1yrs) who had underwent new generation DES (cobalt-chromium everolimus-eluting stent, Xience (n=33); or biolimus-eluting stent, Nobori (n=27)) in left ascending coronary artery at 9 months before and examined plasma levels of tumor necrosis factor (TNF) α, interleukin-6 (IL-6), and high sensitivity C-reactive protein (hs-CRP) in the chronic phase without acute inflammation findings. Patients were divided into 3 groups: presence of both coronary spasm and DM (n=18), presence of each spasm or DM (n=31), and non-spasm and non-DM (n=11). Results: Coronary spasm was induced in 31 (51.6%) of 60 patients. Levels of TNFα, IL-6, and hs-CRP in spasm and DM group were increased compared with those in non-spasm and non-DM group (TNFα; 2.123±0.441 vs. 1.267±0.079 pg/ml, P=0.073: IL-6; 2.668±0.429 vs. 1.346±0.241 pg/ml, P=0.039: hs-CRP; 0.183±0.208 vs. 0.058±0.042 mg/dl, P=0.037). Levels of TNFα, IL-6, and hs-CRP in the each spasm or DM group were in between spasm / DM group and non-spasm / non-DM group, respectively (TNFα, 1.901±0.841pg/ml; IL-6, 2.125±0.651pg/ml; hs-CRP; 0.091±0.073mg/dl). Coronary spasm was not induced in statin-users among the total patients, and non-use of statin was associated with positive for coronary spasm (P=0.041) and increased inflammation levels. Conclusions: Coexistence of coronary spasm and DM in the chronic phase after new generation DES implantation may be associated with low-grade inflammation. The prevention of coronary spasm is related to the use of statin.
Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan
Authors: K. Ohta, P.-J. Bousquet, H. Aizawa, K. Akiyama, M. Adachi, M. Ichinose, M. Ebisawa, G. Tamura, A. Nagai, S. Nishima, T. Fukuda, A. Morikawa, Y. Okamoto, Y. Kohno, H. Saito, H. Takenaka, L. Grouse, J. Bousquet
Journal: Allergy (2011)

To cite this article: Ohta K, Bousquet P-J, Aizawa H, Akiyama K, Adachi M, Ichinose M, Ebisawa M, Tamura G, Nagai A, Nishima S, Fukuda T, Morikawa A, Okamoto Y, Kohno Y, Saito H, Takenaka H, Grouse L, Bousquet J. Prevalence and impact of rhinitis in asthma: SACRA, a cross-sectional nation-wide study in Japan. Allergy 2011; 66: 1287–1295. Background: Asthma and rhinitis are common co-morbidities everywhere in the world but nation-wide studies assessing rhinitis in asthmatics using questionnaires based on guidelines are not available. Objective: To assess the prevalence, classification, and severity of rhinitis using the Allergic Rhinitis and its Impact on Asthma (ARIA) criteria in Japanese patients with diagnosed and treated asthma. Methods: The study was performed from March to August 2009. Patients in physicians' waiting rooms, or physicians themselves, filled out questionnaires on rhinitis and asthma based on ARIA and Global Initiative for Asthma (GINA) diagnostic guides. The patients answered questions on the severity of the diseases and a Visual Analog Scale. Their physicians made the diagnosis of rhinitis. Results: In this study, 1910 physicians enrolled 29 518 asthmatics; 15 051 (51.0%) questionnaires were administered by physician, and 26 680 (90.4%) patients were evaluable. Self- and physician-administered questionnaires gave similar results. Rhinitis was diagnosed in 68.5% of patients with self-administered questionnaires and 66.2% with physician-administered questionnaires. In this study, 994 (7.6%) patients with self-administered and 561 (5.2%) patients with physician-administered questionnaires indicated rhinitis symptoms on the questionnaires without a physician's diagnosis of rhinitis. Most patients with the physician's diagnosis of rhinitis had moderate/severe rhinitis. Asthma control was significantly impaired in patients with a physician's diagnosis of rhinitis for all GINA clinical criteria except exacerbations. There were significantly more patients with uncontrolled asthma as defined by GINA in those with a physician's diagnosis of rhinitis (25.4% and 29.7%) by comparison with those without rhinitis (18.0% and 22.8%). Conclusion: Rhinitis is common in asthma and impairs asthma control.
When are the seeds of postoperative pressure sores sown?
Authors: M. Bliss, B. Simini
Journal: BMJ (1999)

Pressure sores are often thought to be slothful chronic wounds forming slowly because of poor nursing.1 In fact, they are acute injuries which develop rapidly when compression of tissues causes ischaemia and necrosis during serious illness and trauma, including surgery.2 Many of the situations predisposing to pressure sores are well known (though often less well acted on), but those that arise before, during, and after surgery deserve more attention than they have received. In the United States it has been suggested that up to a quarter of pressure sores that develop in hospital originate in the operating theatre.3

Protracted squeezing of tissues between weight bearing surfaces and bony prominences cannot account for the whole pathogenesis of bedsores. An endogenous factor must be invoked that is common to the diverse conditions predisposing to pressure injury—namely, old age, malnutrition, alcohol abuse, diabetes, advanced cancer, terminal illness, sepsis, and vascular and neurological disease. These are all conditions in which multiple organs tend to fail because of failure of the microcirculation. Accordingly, pressure sores should be viewed as the result of yet another organ …
A case of Bazex-Dupré-Christol syndrome associated with multiple genital trichoepitheliomas
Authors: A. Yung, J.A. Newton-Bishop
Journal: British Journal of Dermatology (2005)

Journal Article A case of Bazex–Dupré–Christol syndrome associated with multiple genital trichoepitheliomas Get access A. Yung, A. Yung Department of Dermatology, Leeds General Infirmary, Leeds LS1 3EX, U.K. Department of Dermatology, St James's University Hospital, Leeds LS9 7TF, U.K. E‐mail: Anthony.Yung@leedsth.nhs.uk; ants_ange@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar J.A. Newton‐Bishop J.A. Newton‐Bishop Department of Dermatology, Leeds General Infirmary, Leeds LS1 3EX, U.K. Department of Dermatology, St James's University Hospital, Leeds LS9 7TF, U.K. E‐mail: Anthony.Yung@leedsth.nhs.uk; ants_ange@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 153, Issue 3, 1 September 2005, Pages 682–684, https://doi.org/10.1111/j.1365-2133.2005.06819.x Published: 01 September 2005
A memorable patient: A very rare bleeding disorder
Authors: S. V Ramanan
Journal: BMJ (1998)

As a haematologist, I am often asked to evaluate patients for a possible bleeding disorder. A common story is that the patient has begun to notice bruising for which no antecedent cause can be identified. Many of the patients are young women who often present in early summer when they are more concerned about cosmetic disfigurement than a serious blood disorder. Such a patient came to me a few years ago. A secretary in her mid 20s, she had noticed the appearance of …
Transcatheter aortic valve replacement reduced mortality more than usual care in inoperable severe aortic stenosis
Authors: James Brophy
Journal: Annals of Internal Medicine (2015)

Source Citation Kapadia SR, Leon MB, Makkar RR, et al; PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Mar 15. Epub ahead of print. 25788231
308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study
Authors: F. Le Duff, E. Fontas, D. Giacchero, L. Sillard, J.-P. Lacour, J.-P. Ortonne, T. Passeron
Journal: British Journal of Dermatology (2010)

Background The 308-nm excimer laser and 308-nm excimer lamp have both been shown to be effective in treating vitiligo but a direct comparison has never been performed. Objectives To test the equivalence of these two devices for treating nonsegmental vitiligo. Patients and methods A randomized monocentric study was undertaken. One lesion was treated with the 308-nm excimer laser and its counterpart with the 308-nm excimer lamp. Lesions were treated twice weekly with the same dose on both sides for a total of 24 sessions. The evaluation was done by two independent physicians blinded to the treatment on direct light and ultraviolet light photos. Results Twenty patients were included: 17 completed the study and 104 lesions were treated. The two treatments showed similar results in terms of efficacy for a repigmentation of at least 50% (P = 0·006). The lamp induced more erythema than the laser. Conclusions The 308-nm excimer lamp and laser showed a similar efficacy in treating vitiligo. For the same fluence, the lamp induced more erythema suggesting photobiological differences between the two devices.